Tradestie Institutional Equity Comparison Engine
JANX vs MLTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MLTX Overall Edge
MLTX Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, JANX trades at N/M Forward P/E with -599.3% operating margin (-7.1% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, JANX sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
JANX N/M vs MLTX N/M Fwd P/E
Growth & Margin Winner
MLTX
Op Margin -599.3% vs 0.0% ยท YoY -7.1% vs +0.0%
Momentum & Technical Winner
MLTX
1Y -60.0% vs -5.7% ยท 52W Pos 1% vs 17%
Options & Structure Winner
MLTX
BREAKDOWN (11th %ile IV) vs BREAKDOWN (7th %ile IV)
JANX
NASDAQ
Janux Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$10.97
-3.47% 1D
Market Cap
$703.3M
1M Return
-33.53%
1Y Return
-60.03%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 35.0
Fund 51.0
Flow 67.0
Mom 55.0
MLTX
NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap
$1.1B
1M Return
+24.08%
1Y Return
-5.65%
Forward P/E
N/M
Unified AI Score
38.3 / 100
SELL
Tech 32.0
Fund 44.0
Flow 75.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
JANX -60.03%
MLTX -5.65%
Spread: +54.38 pp (MLTX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
JANX TTM Op. Margin: -599.3%
MLTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JANX vs MLTX. Trailing 12-month operating profitability (JANX -599.3% vs MLTX 0.0%) and valuation multiples (JANX N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | JANX | MLTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $703.3M | $1.1B | Larger Scale | MLTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -7.1% | +0.0% | Higher Growth | MLTX |
| Operating Margin (TTM) Profitability | -599.3% | 0.0% | Higher Margin | MLTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -10.6% | -81.5% | Higher ROE | JANX |
| 52-Week Range Position Momentum | 1% ($11โ$35) | 17% ($9โ$23) | Stronger Trend | MLTX |
| Beta / 30D Volatility Risk Regime | 0.73ฮฒ ยท 118% Vol | 1.61ฮฒ ยท 90% Vol | Lower Realized Risk | MLTX |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 38.3 / 100 (SELL) | Higher Composite | JANX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full JANX vs MLTX Buy Guide
JANX
BREAKDOWN
51d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
MLTX
BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
7th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither JANX nor MLTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.